Christopher J D Wallis1, Alyson L Mahar1, Raj Satkunasivam1, Sender Herschorn1, Ronald T Kodama1, Yuna Lee2, Girish S Kulkarni3, Steven A Narod4, Robert K Nam5. 1. Division of Urology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Canada. 2. Department of Medicine, St. Michael's Hospital, University of Toronto, Canada. 3. Division of Urology, University Health Network, University of Toronto, Canada. 4. Department of Public Health Sciences, University of Toronto, Canada. 5. Division of Urology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Canada. Electronic address: robert.nam@utoronto.ca.
Abstract
OBJECTIVE: To examine the impact of androgen deprivation therapy (ADT) and primary treatment modality on cardiovascular and skeletal-related events and to investigate potential effect modification in a contemporary cohort of patients treated for clinically localized prostate cancer. SUBJECTS AND METHODS: We conducted a retrospective cohort study using Surveillance, Epidemiology, and End Results-Medicare linked databases for men aged 65-79 years who underwent radical prostatectomy or radiotherapy for cT1 or cT2 prostate cancer from 2000 to 2008. We categorized treatment according to primary therapy and receipt of ADT. We described the cumulative incidence of cardiovascular and skeletal-related events. RESULTS: Among 60,156 men, 14,403 underwent surgery and 45,753 underwent radiotherapy. Median follow-up was 6.0 years. After adjusting for baseline differences, treatments with radiotherapy (adjusted hazard ratios [aHR] 1.16-1.28, P <.0001-.04) and ADT (aHR 1.18-1.32, P <.0001-.008) were each independently associated with increased risk of coronary heart disease, sudden cardiac death, fracture, and fracture requiring hospitalization. Radiotherapy was associated with an increased risk of myocardial infarction (aHR 1.20, P = .02), whereas ADT was not (P = .5). We did not identify a significant statistical interaction between primary and hormonal treatment. CONCLUSION: Care for cardiovascular and skeletal-related events is an important part of the survivorship phase for a significant proportion of patients with localized prostate cancer. Increasing use of ADT for patients with localized disease undergoing radiotherapy and the observed higher prevalence of these events in these patients should be considered when discussing the risks and benefits of treatment for localized prostate cancer and when formulating a survivorship plan.
OBJECTIVE: To examine the impact of androgen deprivation therapy (ADT) and primary treatment modality on cardiovascular and skeletal-related events and to investigate potential effect modification in a contemporary cohort of patients treated for clinically localized prostate cancer. SUBJECTS AND METHODS: We conducted a retrospective cohort study using Surveillance, Epidemiology, and End Results-Medicare linked databases for men aged 65-79 years who underwent radical prostatectomy or radiotherapy for cT1 or cT2prostate cancer from 2000 to 2008. We categorized treatment according to primary therapy and receipt of ADT. We described the cumulative incidence of cardiovascular and skeletal-related events. RESULTS: Among 60,156 men, 14,403 underwent surgery and 45,753 underwent radiotherapy. Median follow-up was 6.0 years. After adjusting for baseline differences, treatments with radiotherapy (adjusted hazard ratios [aHR] 1.16-1.28, P <.0001-.04) and ADT (aHR 1.18-1.32, P <.0001-.008) were each independently associated with increased risk of coronary heart disease, sudden cardiac death, fracture, and fracture requiring hospitalization. Radiotherapy was associated with an increased risk of myocardial infarction (aHR 1.20, P = .02), whereas ADT was not (P = .5). We did not identify a significant statistical interaction between primary and hormonal treatment. CONCLUSION: Care for cardiovascular and skeletal-related events is an important part of the survivorship phase for a significant proportion of patients with localized prostate cancer. Increasing use of ADT for patients with localized disease undergoing radiotherapy and the observed higher prevalence of these events in these patients should be considered when discussing the risks and benefits of treatment for localized prostate cancer and when formulating a survivorship plan.
Authors: Kim Edmunds; Haitham Tuffaha; Daniel A Galvão; Paul Scuffham; Robert U Newton Journal: Support Care Cancer Date: 2020-01-07 Impact factor: 3.603
Authors: Ruth E Ashton; Garry A Tew; Wendy A Robson; John M Saxton; Jonathan J Aning Journal: Support Care Cancer Date: 2019-04-10 Impact factor: 3.603
Authors: Andrew L Laccetti; Benjamin Garmezy; Lianchun Xiao; Minas Economides; Aradhana Venkatesan; Jianjun Gao; Eric Jonasch; Paul Corn; Amado Zurita-Saavedra; Landon C Brown; Chester Kao; Emily N Kinsey; Rajan T Gupta; Michael R Harrison; Andrew J Armstrong; Daniel J George; Nizar Tannir; Pavlos Msaouel; Amishi Shah; Tian Zhang; Matthew T Campbell Journal: Cancer Med Date: 2021-03-01 Impact factor: 4.452
Authors: Thiago Gagliano-Jucá; Thomas G Travison; Philip W Kantoff; Paul L Nguyen; Mary-Ellen Taplin; Adam S Kibel; Grace Huang; Richelle Bearup; Haley Schram; Robert Manley; Yusnie M Beleva; Robert R Edwards; Shehzad Basaria Journal: J Endocr Soc Date: 2018-04-20